



EXPRESS MAIL CERTIFICATE

Date 5/22/02

Label No. EL3632877374S

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

CATHERINE RONAI
Catherine Ronai
Signature

14
PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 2420/11249US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ze'ev RONAI

Serial No.: 10/076,905

Confirmation No.: 1884

Filed: February 14, 2002

For: INHIBITION OF ATF2 ACTIVITY TO TREAT CANCER

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: May 21, 2002


Paul F. Fehlner, Ph.D.
Registration No. 35,135
Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700

Serial No. 10/076,905

Docket No. 2420/1I249US2



LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 2420/1I249US2 SERIAL NO: 10/076,905
APPLICANT: Ze'ev RONAI FILING DATE: February 14, 2002
CONFIRMATION NO: 1884

U.S. PATENT DOCUMENTS

*EXAMINER DOCUMENT
INITIALS NUMBER DATE NAME CLASS SUBCLASS FILING DATE

FOREIGN PATENT DOCUMENTS

*EXAMINER DOCUMENT TRANSLATION
INITIALS NUMBER DATE COUNTRY CLASS SUBCLASS YES NO

OTHER REFERENCES

SEARCHED INDEXED FILED
(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)

* EXAMINER
INITIALS

1. Bhoumik *et al.*, Clin. Cancer Res. 2001; 7(2):331-42. ✓
2. Ivanov, V.N., and Ronai, Z., Oncogene 2000; 19: 3003-3012. ✓
3. Ivanov, V.N. *et al.*, Oncogene 2000; 19: 933-942. ↴
4. Yang, Y.-M *et al.*, Oncogene, 12 :2223-2233, 1996. ✓
5. Ronai, Z. *et al*, Oncogene 1998; 16: 523-531. ✓
6. Ivanov, V.N. *et al.*, J. Biol. Chem. 1999; 274:14079-14089. ✓

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 2420/11249US2 SERIAL NO: 10/076,905
APPLICANT: Ze'ev RONAI FILING DATE: February 14, 2002
CONFIRMATION NO: 1884

***EXAMINER
INITIALS**

7. Gupta, S. *et al.*, Science 1995; 267: 389-393. ✓
8. Fuchs, S.Y. and Ronai, Z., Mol. Cell Biol. 1999; 19: 3289-3298. ✓
9. Georgopoulos, K. *et al.*, Mol. Cell. Biol. 1992; 12: 747-757. ✓
10. Huguier S. *et al.*, Mol. Cell Biol. 1988; 18:7020-7029. ✓
11. Bhoumik, A. *et al.*, ATF-2 derived peptide sensitizes melanoma to treatment and inhibits *in vivo* growth and metastasis through altered ATF-2 and c-Jun transcriptional activities. (manuscript submitted to *Cancer Cell*) ✓

EXAMINER: _____

DATE CONSIDERED: _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.